DRG Market Assessment reports

Introduction: This research explores the reimbursement and utilization landscape for acute coronary syndrome (ACS) drugs and the impact of accountable care organizations (ACOs) on payers’ and…

Based on DRG’s gold-standard Epidemiology data, the Interactive Patient Flow Model provides insight into the epidemiology of HCV for five different treatment scenarios.With the introduction of…

For the estimated 3 million people in the United States who have Alzheimer’s disease (AD), approved treatment is limited to five procognitive symptomatic therapies (e.g., donepezil, memantine)…

Retinitis pigmentosa (RP) is a rare genetic disorder marked by retinal degeneration, progressive vision loss, and eventual blindness. There are no approved pharmacotherapies for RP, and current…

In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of…

Hypertension is a chronic condition that can be effectively managed by a vast array of drugs, spanning many drug classes. The antihypertensive market is highly mature and most of its drug classes…

Hyperaldosteronism is a disorder that is characterized by the excessive release of aldosterone into the blood and is a common cause of secondary hypertension. The main goals of treatment are the…

The triptan drug class dominates the prescription acute treatment migraine market, particularly now that the class is almost fully generic. Despite the array of approved treatment options, new…

According to DRG epidemiology, more than 35 million people in the United States suffer migraines, and more than 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a…

Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded…

MARKET OUTLOOK U.S. gastroenterologists generally follow a step-up approach when treating Crohn’s disease patients that begins with safe, albeit often less-efficacious, therapies (e.g.,…

First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, oral beta blocker, and oral diuretic. Second- or third-line treatments is…